Management of Myelofibrosis: from Diagnosis to New Target Therapies.
Opinion Statement: Myelofibrosis (MF) is a clonal disorder of the pluripotent hematopoietic stem cell, whose clinical manifestations can be extremely heterogeneous, including cytopenias, organomegaly, constitutional symptoms, and cachexia. Median survival ranges from approximately 3.5 to 5.5 years;...
| Publicado en: | Current Treatment Options in Oncology Vol. 21; no. 6; pp. 1 - 15 |
|---|---|
| Autores principales: | , , |
| Formato: | review Journal Article |
| Publicado: |
Springer Nature
Jun2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=143759532&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 143759532 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15272729 3KHC jtl: Current Treatment Options in Oncology issn: 15272729 maglogo: N pubinfo: dt: Jun2020 vid: 21 iid: 6 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 143759532 143759532 NLM32350623 143759532 10.1007/s11864-020-00734-y NLM32350623 143759532 ppf: 1 ppct: 14 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Management of Myelofibrosis: from Diagnosis to New Target Therapies. aug: au: Iurlo, Alessandra Cattaneo, Daniele Bucelli, Cristina affil: Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122, Milan, Italy sug: subj: Primary Myelofibrosis Diagnosis Primary Myelofibrosis Therapy Treatment Outcomes Drug Therapy Methods Primary Myelofibrosis Etiology Disease Susceptibility Disease Management Combined Modality Therapy Methods Protein Kinase Inhibitors Adverse Effects Protein Kinase Inhibitors Therapeutic Use Drug Therapy, Combination Drug Therapy Adverse Effects Protein Kinase Inhibitors Administration and Dosage Algorithms Impact of Events Scale Scales Ferrans and Powers Quality of Life Index ab: Opinion Statement: Myelofibrosis (MF) is a clonal disorder of the pluripotent hematopoietic stem cell, whose clinical manifestations can be extremely heterogeneous, including cytopenias, organomegaly, constitutional symptoms, and cachexia. Median survival ranges from approximately 3.5 to 5.5 years; while the most frequent cause of death is the evolution to acute myeloid leukemia, also other conditions such as progression without transformation, complications due to cytopenias including infections or bleeding, and cardiovascular events may be fatal. Myelofibrosis is still orphan of curative treatments: allogeneic hematopoietic stem cell transplant (HSCT), the only therapeutic approach that has clearly demonstrated an impact on disease progression, is associated with relevant morbidity and mortality and only a minority of patients is eligible for such an intensive procedure. While the discovery of the crucial role of JAK2 mutations and the consequent clinical use of JAK inhibitors has led to a dramatic improvement of symptoms control and quality of life, yet these drugs do not significantly modify the natural history of the disease. A better understanding of the molecular pathogenesis will hopefully foster the development of new targeted therapies aimed at improving MF prognosis. Herein, we review the most recent advances about JAK inhibitors and other molecules which are under investigation. pubtype: Academic Journal doctype: review Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|